Lake Zurich, Illinois, November 10 (ots/PRNewswire) -
Fenwal Inc., a global medical technology company focused on
improving blood collection, separation, safety and availability,
announced today William H. Cork has joined the company as senior vice
president and chief technology officer. Mr. Cork, 50, will lead
Fenwal's research and development, regulatory and clinical affairs
teams, reporting to Ron K. Labrum, Fenwal's president and chief
Mr. Cork joins Fenwal from Northbrook, Illinois-based Nanosphere
Inc. (Nasdaq: NSPH), where he was chief technology officer and vice
president of research and development since 2001. Nanosphere focuses
on molecular diagnostic testing.
Prior to this, Mr. Cork was vice president of research and
development for Fenwal (then a division of Baxter International),
where he led the development and global commercialization of platelet
and cell-collection technologies, including Fenwal's Amicus and
CS-3000 separator portfolios.
"Bill is a strong and experienced scientific leader, with deep
knowledge of advanced molecular science, software development and
transfusion medicine with clinical relationships worldwide," Labrum
said. "His decade-long tenure with us in the 1990s was one of the
most innovative and productive periods in Fenwal's recent history."
Mr. Cork holds more than 15 medical-technology patents and has
another seven pending. He earned a bachelor's degree in electrical
engineering from Northwestern University, where he also minored in
biomedical engineering. Mr. Cork replaces Hiroshi Uchida as a member
of Fenwal's executive team. Mr. Uchida transitioned last month to
Fenwal's board of directors.
Fenwal Inc. is a global medical technology company focused on
improving blood collection, separation, safety and availability for
patient care. Fenwal became an independent company in 2007, but its
roots go back to 1949 with the founding of Fenwal Laboratories.
Fenwal developed the first flexible, disposable container for blood
collection, eliminating complications associated with glass
containers and allowing blood to be separated into therapeutic
components. Today, the company's products and advanced collection and
separation technologies are used throughout the world to help ensure
a safe and available supply of lifesaving blood and blood products.
Fenwal Inc. is based in Lake Zurich, Illinois. For more information,
please visit www.fenwalinc.com.
ots Originaltext: Fenwal Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Tanya Tyska of Fenwal Inc., +1-847-550-2732,